MorphoSys most recent financial guidance for fiscal year 2014 was published on 28 February 2014. MorphoSys expects total Group revenues of EUR 58 million to EUR 63 million and anticipates an EBIT in the range of EUR -11 to EUR -16 million in 2014. Investments in proprietary products and technologies will amount to EUR 36 million to EUR 41 million, not including expenses for additional development programs, which might be in-licensed during 2014.
|in € million||2014||2013|
|Group Revenues||58 - 63||78.0|
|Group EBIT||-11 to -16||9.9|
|Investment||36 - 41||31.7|